Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Changchun Fudan-Zhongzhi Pharmaceutical is a Chinese biopharmaceutical company focused on the development, manufacturing, and commercialization of recombinant protein therapeutics and small molecule drugs. The company is best known for its production of recombinant human interferon alpha-2b products, which are utilized in the treatment of various viral infections and dermatological conditions. Based in the High-tech Industrial Development Zone of Changchun, the firm operates GMP-certified facilities to ensure high-quality production of its biological and chemical pharmaceutical portfolio. Its business model integrates research and development with large-scale manufacturing to serve the domestic Chinese healthcare market.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Fudan-Changchun.